🇺🇸 Janssen Ad26.COV2.S in United States
6 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 6
Most-reported reactions
- Decreased Appetite — 2 reports (33.33%)
- Nausea — 2 reports (33.33%)
- Q Fever — 2 reports (33.33%)
Frequently asked questions
Is Janssen Ad26.COV2.S approved in United States?
Janssen Ad26.COV2.S does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Janssen Ad26.COV2.S in United States?
Alvea Holdings, LLC is the originator. The local marketing authorisation holder may differ — check the official source linked above.